Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Pluristem Therapeutics, Inc. (PSTI) Applies For Orphan Drug Designation For PLX Cells To Treat Preeclampsia 0 comments
    Feb 21, 2014 1:46 PM | about stocks: PSTI

    Leading placenta-based cell therapies developer Pluristem Therapeutics announced it is submitting its application to the FDA to request Orphan Drug Designation for its PLacental eXpanded (PLX-PAD) cells for treating severe preeclampsia.

    Receiving Orphan Drug Designation can qualify a company for various benefits under the Orphan Drug Act of 1983 (ODA), as amended, including a seven-year period of orphan drug exclusivity upon approval of the product, a tax credit for certain clinical testing expenses for the orphan drug, written guidance on the nonclinical and clinical studies necessary for obtaining market approval of an orphan drug, and orphan drug grants.

    Pluristem recently established a preeclampsia steering committee featuring key medical opinion leaders, and this Orphan Drug application submission is an important step for the company in advancing its preeclampsia development program. The great unmet medical need for preeclampsia makes this indication one of the company's top priorities. Pluristem looks forward to advancing into human trials and is hopeful that strong preclinical data for PLX cells will lead to similar findings at the clinical level.

    Orphan Drug Designation has been successfully received by Pluristem for PLX cells in two other indications: treatment of aplastic anemia and treatment of Buerger's disease.

    For more information about Pluristem, visit pluristem.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: PSTI
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.